Access to medicine is a vital issue at the crossroads of global health issue, corporate responsibility, and ESG investing. Join us as we unpack barriers to equitable access, explore how pharmaceutical companies and ESG-focused investors are addressing these challenges, the emergence of patient reach is as a measure of progress, and how improvements in reporting can align access initiatives with business models to drive both sustainable growth and social impact.

Birgit Lundem Jakobsen, ESG Specialist at PGIM, hosts this discussion with Bram Wagner, Investor Engagement Lead for the Access to Medicine Foundation, and Hank Balbirer, CFA, U.S. Investment Grade Senior Credit Research Analyst at PGIM.

Recorded on November 5, 2025.

As the International Maritime Organization (IMO) presses to implement their groundbreaking Greenhouse Gas Fuel Intensity Standards across the shipping industry, we examine the scope and likely impacts of these net-zero regulations. Get our take on the credit implications to the industry—including progress on the transition to alternative fuels—as well as considerations for investors in this growing sector.

PGIM's Roma Wilkinson, ESG Specialist, hosts this discussion with Sean Goodier, CFA, European Investment Grade Credit Research Analyst.

Recorded on September 3, 2025.

EU ESG regulations significantly impact companies operating within the EU, necessitating precise actions and accountability. This episode of Fixed on ESG outlines the key institutions responsible for shaping EU ESG regulations and the various forms these regulations can take, including sustainability frameworks and reporting obligations to investment classifications. We will examine the current trajectory for regulatory changes, including the Omnibus package, against Europe's shifting political and economic contours.

PGIM's Birgit Lundem Jakobsen, ESG Specialist, hosts this discussion with Judith Franken, EMEA Government Affairs.

Recorded on August 26, 2025.